A critically ill client with a triple-lumen central venous catheter is prescribed multiple continuous intravenous (IV) infusions, including norepinephrine, unfractionated heparin, and pantoprazole. Which of the following nursing actions are appropriate to ensure the safe administration of these parenteral therapies? Select all that apply.
- Dedicate a separate, distinct lumen of the central venous catheter exclusively for the continuous norepinephrine infusion.Answer
- Consult a drug reference guide to verify Y-site compatibility prior to administering any intermittent intravenous piggyback medications.Answer
- CPause the continuous heparin infusion, administer an incompatible intravenous push medication through the same lumen, and immediately resume the heparin.
- DCalculate the norepinephrine continuous infusion rate based on the client's estimated ideal body weight rather than their documented actual body weight.
- EDelegate the task of assessing the central venous catheter insertion site for signs of extravasation to the unlicensed assistive personnel.
- Scrub the needleless connector hub with an appropriate antiseptic for at least 15 seconds prior to accessing any port.Answer
Answer
The appropriate nursing actions include dedicating a specific lumen for norepinephrine, verifying Y-site compatibility prior to piggyback administrations, and vigorously scrubbing the needleless connector hub before access.
Safe parenteral therapy requires evidence-based practices: vasoactive infusions like norepinephrine must have a dedicated lumen to prevent accidental bolusing during line flushes. Furthermore, nurses must always verify Y-site compatibility to prevent medication precipitation, and rigorous scrubbing of needleless connectors is mandatory to prevent central line-associated bloodstream infections.
Step-by-Step Solution
Key Concept
Safe administration of complex parenteral therapies requires strict adherence to infection control, verification of IV compatibility, accurate weight-based dosing, and dedicated lines for continuous vasoactive medications.